header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

SHOULD HIGH RISK PATIENTS WHO ARE IMMOBILISED IN BELOW KNEE CASTS BE ANTI-COAGULATED?



Abstract

Aim: This study was undertaken to assess the incidents of Deep Vein Thrombosis (DVT) and/or Pulmonary Embolus (PE) in orthopaedics outpatients who were immobilised in lower limb casts.

Materials and Methods: We retrospectively analysed the incidents of DVT/PE in a district general hospital over a one year period in orthopaedic outpatients who had their lower limb immobilised. Only patients who were no already on anti-coagulants were included and patients with co-morbidity associated with a higher risk of thrombosis were excluded. The diagnosis of DVT was made by ultrasound scan and PE confirmed with a CT pulmonary angiogram. The details of patients who were found to have a clot were cross checked with the outpatient plaster room register. The relevant case notes were then studied.

Results: There were three hundred and eighty patients who had lower limb casts, six of whom developed a blood clot during the period of immobilisation. All patients were male -and four patients presented with a DVT and two patients presented with a pulmonary embolism, all patients survived.

There were two smokers and one patient was very overweight.

Discussion: Incidents of DVT among patients with lower limb casts are low. At present there is no guideline on the use of DVT prophylaxis in orthopaedic outpatients. Our results show that even though the number of proven DVTs is low, the potential of developing a fatal pulmonary embolus in these patients is present.

Conclusion: DVT prophylaxis could be considered for orthopaedic outpatients who are treated with lower limb casts and who have additional risk factors. A larger prospective survey is required before guidelines regarding prophylaxis can be drawn up.

Correspondence should be addressed to Ms Larissa Welti, Scientific Secretary, EFORT Central Office, Technoparkstrasse 1, CH-8005 Zürich, Switzerland